Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17355568 | 0.97 | CYP2C9 (0.31) | CYP2C9CYP3A4APPALDH1A1LMNA | |
| SCHEMBL17355538 | 0.94 | CYP2C9 (0.37) | CYP2C9CYP3A4APPALDH1A1LMNA | |
| SCHEMBL17369388 | 0.91 | GRM2 (0.33) | CYP2C9CYP3A4APPFFAR4 | |
| SCHEMBL19829720 | 0.89 | CYP3A4 (0.31) | CYP2C9CYP3A4APP | |
| SCHEMBL17369475 | 0.87 | CYP2C9 (0.35) | CYP2C9CYP3A4APPALDH1A1LMNA | |
| SCHEMBL19829685 | 0.87 | CYP3A4 (0.31) | CYP2C9CYP3A4APP | |
| SCHEMBL17368023 | 0.86 | P2RY14 (0.32) | FFAR4DGAT1 | |
| SCHEMBL17355526 | 0.86 | CYP3A4 (0.30) | CYP2C9CYP3A4APP | |
| SCHEMBL7730231 | 0.86 | CYP2C9 (0.33) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL17377926 | 0.86 | CYP3A4 (0.34) | CYP2C9CYP3A4APPESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657229-B2 | Liquid crystal compound having difluoromethyleneoxy, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9657229-B2 | Liquid crystal compound having difluoromethyleneoxy, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-05-23 | — | — | US | disclosed |
| US-20150376502-A1 | LIQUID CRYSTAL COMPOUND HAVING DIFLUOROMETHYLENEOXY, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150376502-A1 | LIQUID CRYSTAL COMPOUND HAVING DIFLUOROMETHYLENEOXY, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2015-12-31 | — | — | US | disclosed |
| EP-2957554-A1 | LIQUID-CRYSTALLINE COMPOUND HAVING DIFLUOROMETHYLENEOXY GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2015-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376502-A1 | LIQUID CRYSTAL COMPOUND HAVING DIFLUOROMETHYLENEOXY, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | C1S, CPNE4, PIEZO1 | CYP2C9 1827/4885CYP3A4 1562/4885APP 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.